Replies to post #52208 on OWC Pharmaceutical Research Corp (OWCP)

[Triple9]

I love the comparisons to GWPH, but I own some GWPH (very conflicted about that BTW) and I've done my DD. GWPH looks expensive, but Goldman Sachs has a price target of $189 and a buyout target price of $349. I'm gonna sell my GWPH because of what they are doing, but for those who want to make this comparison know that GWPH is deemed as undervalued right now too.

Goldman Sachs initiated coverage on GW Pharma (NASDAQ: GWPH) with a Buy rating and a price target of $189, implying upside of 42%. Analyst Salveen Richter sees potential for $1.6 billion in worldwide sales for lead asset Epidiolex. In an M&A scenario the stock could be worth $349, the firm said.

http://www.streetinsider.com/Analyst+Comments/Goldman+Sachs+Sees+42%25+Upside+in+GW+Pharma+(GWPH)+and+Initiates+Coverage+at+Buy/12113118.html